247 related articles for article (PubMed ID: 16777680)
1. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
7. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
8. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).
Atobe K; Ishida T; Ishida E; Hashimoto K; Kobayashi H; Yasuda J; Aoki T; Obata K; Kikuchi H; Akita H; Asai T; Harashima H; Oku N; Kiwada H
Biol Pharm Bull; 2007 May; 30(5):972-8. PubMed ID: 17473445
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 immunoliposomes for targeted therapy of human tumors.
Park JW; Hong K; Kirpotin DB; Meyer O; Papahadjopoulos D; Benz CC
Cancer Lett; 1997 Oct; 118(2):153-60. PubMed ID: 9459205
[TBL] [Abstract][Full Text] [Related]
10. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
11. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity.
Pan X; Lee RJ
Int J Pharm; 2007 May; 336(2):276-83. PubMed ID: 17212981
[TBL] [Abstract][Full Text] [Related]
12. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
[TBL] [Abstract][Full Text] [Related]
13. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma.
Lehtinen J; Raki M; Bergström KA; Uutela P; Lehtinen K; Hiltunen A; Pikkarainen J; Liang H; Pitkänen S; Määttä AM; Ketola RA; Yliperttula M; Wirth T; Urtti A
PLoS One; 2012; 7(7):e41410. PubMed ID: 22844475
[TBL] [Abstract][Full Text] [Related]
14. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.
Pan X; Wu G; Yang W; Barth RF; Tjarks W; Lee RJ
Bioconjug Chem; 2007; 18(1):101-8. PubMed ID: 17226962
[TBL] [Abstract][Full Text] [Related]
16. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells.
Li T; Amari T; Semba K; Yamamoto T; Takeoka S
Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
Harding JA; Engbers CM; Newman MS; Goldstein NI; Zalipsky S
Biochim Biophys Acta; 1997 Jul; 1327(2):181-92. PubMed ID: 9271260
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]